[Systemic lupus erythematosus].
Hirohata
Shunsei
S
Department of Internal Medicine, Teikyo University School of Medicine.
D000927:Anticonvulsants / Q000627:therapeutic use; D001323:Autoantibodies / Q000097:blood; D015415:Biomarkers / Q000097:blood / Q000134:cerebrospinal fluid; D003520:Cyclophosphamide / Q000627:therapeutic use; D006801:Humans; D007136:Immunoglobulins / Q000134:cerebrospinal fluid; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D016898:Interferon-alpha / Q000134:cerebrospinal fluid; D015850:Interleukin-6 / Q000134:cerebrospinal fluid; D008180:Lupus Erythematosus, Systemic / Q000150:complications*; D020945:Lupus Vasculitis, Central Nervous System / Q000145:classification / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology*; D011239:Prednisolone / Q000008:administration & dosage; D011619:Psychotropic Drugs / Q000627:therapeutic use; D020551:Pulse Therapy, Drug
D000927:Anticonvulsants; D001323:Autoantibodies; D015415:Biomarkers; D007136:Immunoglobulins; D007166:Immunosuppressive Agents; D016898:Interferon-alpha; D015850:Interleukin-6; D011619:Psychotropic Drugs; D003520:Cyclophosphamide; D011239:Prednisolone